Literature DB >> 9529027

Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach.

D J Sonneveld1, D T Sleijfer, H S Koops, M E Keemers-Gels, W M Molenaar, H J Hoekstra.   

Abstract

BACKGROUND: Mature teratoma is often found in resected retroperitoneal residual tumor masses (RRTM) after chemotherapy for disseminated nonseminomatous testicular germ cell tumors (NSTGCT). The aim of this report is to describe the clinical course of patients after resection of residual teratoma, with particular emphasis on relapse with either growing mature teratoma or secondary non-germ cell malignancy.
METHODS: During the period 1979-1995, 113 patients underwent a laparotomy for resection of RRTM after chemotherapy for NSTGCT. Only patients with mature teratoma in the RRTM were included in the current study, and data on the patients who experienced relapse were studied in detail.
RESULTS: Mature teratoma was found in 51 patients (45.1%) with RRTM resected after chemotherapy. Nine of these 51 patients (17.6%) relapsed; the relapses resulted from growing mature teratoma in 5 patients (9.8%), secondary non-germ cell malignancy in 3 patients (5.9%), and recurrent germ cell malignancy in 1 patient (2.0%). The primary treatment for all relapsing patients was surgical excision. All five patients with growing mature teratoma are alive without evidence of disease, as is the patient with recurrent germ cell malignancy. One of the three patients with non-germ cell malignancy died of disease, and the remaining two are alive with disease.
CONCLUSIONS: Long term follow-up after resection of postchemotherapy residual teratoma is indicated because a proportion of patients develop growing mature teratoma or a secondary non-germ cell malignancy. The treatment for these recurrences should be complete surgical excision.

Entities:  

Mesh:

Year:  1998        PMID: 9529027     DOI: 10.1002/(sici)1097-0142(19980401)82:7<1343::aid-cncr18>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

Review 1.  Late relapse of testis cancer.

Authors:  Yaron Ehrlich; Eli Rosenbaum; Jack Baniel
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

2.  ZBTB16: a novel sensitive and specific biomarker for yolk sac tumor.

Authors:  Guang-Qian Xiao; Faqian Li; Pamela D Unger; Hani Katerji; Qi Yang; Loralee McMahon; David E Burstein
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

Review 3.  Postchemotherapy surgery for germ cell tumors--what have we learned in 35 years?

Authors:  Stephen B Riggs; Earl F Burgess; Kris E Gaston; Caroline A Merwarth; Derek Raghavan
Journal:  Oncologist       Date:  2014-04-09

4.  Oligometastatic Growing Teratoma Syndrome: A Case for an Aggressive Surgical Approach.

Authors:  William S Gange; Robert H Blackwell; John Biemer; Güliz A Barkan; Maria M Picken; Marcus L Quek
Journal:  Curr Urol       Date:  2016-09-20

5.  Benign neck metastasis of a testicular germ cell tumor.

Authors:  Haim Gavriel; Stephen Kleid
Journal:  Int Surg       Date:  2015-01

Review 6.  [When is surgical resection of metastases in testicular germ cell tumors indicated and is there a scientific basis?]

Authors:  A Heidenreich; P Paffenholz; F Haidl; D Pfister
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

Review 7.  [Therapy for recurrent testicular cancer].

Authors:  M Kuczyk; M Horstmann; A Merseburger; J Beyer
Journal:  Urologe A       Date:  2005-04       Impact factor: 0.639

8.  Management of poor-prognosis testicular germ cell tumors.

Authors:  Kiranpreet Khurana; Timothy D Gilligan; Andrew J Stephenson
Journal:  Indian J Urol       Date:  2010 Jan-Mar

Review 9.  What radiologists should know about microRNA (miRNA) serum biomarkers for germ cell tumors.

Authors:  Matthew A Morgan; Joanie M Garratt; David J Vaughn
Journal:  Abdom Radiol (NY)       Date:  2020-08-17

10.  Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice.

Authors:  Axel Heidenreich; David Pfister
Journal:  Ther Adv Urol       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.